pharmaphorum5 天
Novartis’ COPD combo show benefits in switching from established drugs
a long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered in a single once-daily dose in GSK’s Ellipta dry powder inhaler. Novartis says ...